GRCE — Grace Therapeutics Share News
0.000.00%
Last trade - 00:00Brief: Grace Therapeutics Announces 2025 Fiscal Year-End Results, Provides Business Update
Brief: Grace Therapeutics Announces Alignment With The FDA Supporting The Submission For Gtx-104
Brief: Matinas BioPharma Appoints Seasoned Biotech Leaders To Board Of Directors
Brief: Grace Therapeutics to offer up to 8.8 mln shares by selling stockholders, SEC Filing shows
Brief: Acasti Announces Corporate Name Change To Grace Therapeutics, Inc.
Brief: Acasti Announces Completion Of Patient Enrollment In Pivotal Phase 3 Strive-On Safety Trial Of Gtx-104
Acasti Pharma Inc reports results for the quarter ended in June - Earnings Summary
Acasti Pharma Inc expected to post a loss of 34 cents a share - Earnings Preview
Brief: Acasti Announces Achievement Of 50% Enrollment In Pivotal Phase 3 Strive-On Safety Trial
Acasti Pharma Inc reports results for the quarter ended in March - Earnings Summary
Brief: Acasti Announces Year-End 2024 Financial Results, Provides Business Update
Acasti Pharma Inc expected to post a loss of 47 cents a share - Earnings Preview
Acasti Pharma Inc reports results for the quarter ended in December - Earnings Summary
Brief: Acasti Announces Third Fiscal Quarter 2024 Financial Results
Brief: Aker Biomarine Acquires Patents, Equipment, And Scientific Data From Acasti Pharma
Brief: Acasti Pharma Entered Into Settlement Agreement With Aker Biomarine Antarctic AS On Oct 18
Brief: Acasti Announces Dosing Of First Patient In Gtx-104 Strive-On Trial
Brief: Acasti Pharma Inc Files For Shelf Of Up To 6.6 Mln Common Shares By Selling Stockholders - SEC Filing
Brief: Acasti Pharma Inc Received Written Notice From Nasdaq Notifying Co It Had Regained Compliance With Minimum Bid Price Requirement